Alinity 08P1021Recalls & reported problems
Abbott Ireland Diagnostics · Alinity i HBsAg Qualitative II Reagent Kit 200 Tests · Class 2
- Adverse event reports
- 4
- Deaths reported
- 0
- Injuries reported
- 0
- Recalls naming it
- 0
Summary
The FDA's MAUDE database contains 4 adverse event reports that list this exact device (DI 00380740136581), received between May 20, 2022 and Jan 3, 2024 — classified as 4 malfunctions.
The most frequently reported specific device problem is “False Positive Result” (4 reports).
Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event, and counts can't be used to compare devices or estimate failure rates. How this data works · Data updated Oct 13, 2026.
Reports received per month
Most reported problems
Device problems
- False Positive Result4
Patient problems
- No Clinical Signs, Symptoms or Conditions4
Recent adverse event reports
The 4 most recent of 4 reports, in the reporter's own words as published by the FDA.
MalfunctionJan 3, 2024False Positive Result; False Positive Result
THE CUSTOMER OBSERVED A FALSE REACTIVE ALINITY I HBSAG QUALITATIVE II RESULT FOR A PATIENT IN THE DIALYSIS UNIT. THE FOLLOWING DATA WAS PROVIDED: INITIAL RESULT A WEEK AGO = NEGATIVE, HEP B VACCINE ADMINISTERED. (B)(6) 2023 SAME PATIENT, NEW SAMPLE. RESULT = POSITIVE FOR BOTH HEP B ANTIGEN AND ANTIBODY. SAMPLE ID (B)(6) INITIAL RESULT = REACTIVE. REPEAT IN DUPLICATE AND BOTH RESULTS = REACTIVE. CONFIRMATORY TEST PERFORMED AND RESULT = REACTIVE. NO IMPACT TO PATIENT MANAGEMENT WAS REPORTED.
Patient problems: No Clinical Signs, Symptoms or Conditions
MAUDE report 18440583 ↗MalfunctionFeb 20, 2023False Positive Result; False Positive Result
THE CUSTOMER OBSERVED FALSE REACTIVE ALINITY I HBSAG QUALITATIVE II AND ALINITY I HBSAG QUALITATIVE II CONFIRMATORY RESULTS FOR A PREGNANT FEMALE PATIENT. THE SAMPLE WAS PULLED AND REPEATED 4 DAYS LATER WITH A NONREACTIVE RESULT. A SECOND SAMPLE WAS DRAWN WHICH GENERATED A NONREACTIVE RESULT. THE FOLLOWING DATA WAS PROVIDED: CUSTOMER STATED THEY HAD A SAMPLE THAT WAS DRAWN ON (B)(6) 2023 THAT RAN ON (B)(6) 2023 AND GAVE THE FOLLOWING RESULTS ACCORDING TO CUSTOMER: SID (B)(6) HBSAG=1.04 HBSAG CONFIRMATORY = REACTIVE. REPEAT OF SAMPLE ON (B)(6) 2023 SAMPLE WAS RESPUN AND RERAN IN DUPLICATE ACCORDING TO CUSTOMER: HBSAG=1.19, HBSAG=1.27, HBSAG CONFIRMATORY = 1.11 CONFIRMED POSITIVE. SAMPLE WAS RERUN ON (B)(6) 2023, RESULT = SID (B)(6) HBSAG=0.33 NONREACTIVE. NEW SAMPLE DRAWN (B)(6) 2023 SID= (B)(6) HBSAG = NONREACTIVE HBSAG CONFIRMATORY = NEGATIVE. PER ALINITY I HBSAG QUALITATIVE II PACKAGE INSERT < 1.00 NONREACTIVE NO RETEST REQUIRED. = 1.00 REACTIVE RETEST IN DUPLICATE NO IMPACT TO PATIENT MANAGEMENT WAS REPORTED.
Patient problems: No Clinical Signs, Symptoms or Conditions
MAUDE report 16403034 ↗MalfunctionFeb 20, 2023False Positive Result; False Positive Result
THE CUSTOMER OBSERVED FALSE REACTIVE ALINITY I HBSAG QUALITATIVE II AND ALINITY I HBSAG QUALITATIVE II CONFIRMATORY RESULTS FOR A PREGNANT FEMALE PATIENT. THE SAMPLE WAS PULLED AND REPEATED 4 DAYS LATER WITH A NONREACTIVE RESULT. A SECOND SAMPLE WAS DRAWN WHICH GENERATED A NONREACTIVE RESULT. THE FOLLOWING DATA WAS PROVIDED: CUSTOMER STATED THEY HAD A SAMPLE THAT WAS DRAWN ON (B)(6) 2023 THAT RAN ON (B)(6) 2023 AND GAVE THE FOLLOWING RESULTS ACCORDING TO CUSTOMER: SID (B)(6) HBSAG=1.04 HBSAG CONFIRMATORY = REACTIVE. REPEAT OF SAMPLE ON (B)(6) 2023 SAMPLE WAS RESPUN AND RERAN IN DUPLICATE ACCORDING TO CUSTOMER: HBSAG=1.19 ; HBSAG=1.27 ; HBSAG CONFIRMATORY = 1.11 CONFIRMED POSITIVE. SAMPLE WAS RERUN ON (B)(6) 2023 RESULT = SID (B)(6) HBSAG=0.33 NONREACTIVE. NEW SAMPLE DRAWN (B)(6) 2023 SID= (B)(6) HBSAG = NONREACTIVE HBSAG CONFIRMATORY = NEGATIVE PER ALINITY I HBSAG QUALITATIVE II PACKAGE INSERT < 1.00 NONREACTIVE NO RETEST REQUIRED. = 1.00 REACTIVE RETEST IN DUPLICATE NO IMPACT TO PATIENT MANAGEMENT WAS REPORTED.
Patient problems: No Clinical Signs, Symptoms or Conditions
MAUDE report 16402197 ↗MalfunctionMay 20, 2022False Positive Result; False Positive Result
THE CUSTOMER OBSERVED FALSE REACTIVE ALINITY I HBSAG RESULTS GENERATED ON AN ALINITY I PROCESSING MODULE FOR TWO PATIENTS THAT CONFIRMED POSITIVE AND WERE NEGATIVE ON AN OTHER METHOD. THE FOLLOWING INFORMATION WAS PROVIDED: SID (B)(6) INITIAL RESULT = 1.35 S/CO, REPEAT RESULTS = 1.25 S/CO AND 1.33 S/CO; HBSAG CONFIRMATORY RESULTS: C1 = 0.35 S/CO, C2=1.86 S/CO, NEUT% = 94%. SAMPLE WAS SENT TO REFERENCE LAB AND CAME BACK NEGATIVE ON UNKNOWN METHODOLOGY. SID (B)(6) INITIAL RESULT = 2.63 S/CO, REPEAT RESULTS = 2.74 S/CO AND 2.72 S/CO; HBSAG CONFIRMATORY RESULTS: C2 = 2.31 S/CO, NEUT% = 97% NO IMPACT TO PATIENT MANAGEMENT WAS REPORTED.
Patient problems: No Clinical Signs, Symptoms or Conditions
MAUDE report 14458054 ↗
Other Test, hepatitis b (b core, be antigen, be antibody, b core igm) devices
- Elecsys HBsAg II 08814848190Roche Diagnostics GmbH · Test, hepatitis b (b core, be antigen, be antibody, b core igm)93 reports
- ARCHITECT 4P53-25Abbott Ireland Diagnostics · Test, hepatitis b (b core, be antigen, be antibody, b core igm)1 recall16 reports
- VITROS 6801925Ortho Clinical Diagnostics · Test, hepatitis b (b core, be antigen, be antibody, b core igm)1 recall15 reports
- ARCHITECT 1L82-27Abbott Ireland Diagnostics · Test, hepatitis b (b core, be antigen, be antibody, b core igm)1 recall4 reports
- VITROS 6801926Ortho Clinical Diagnostics · Test, hepatitis b (b core, be antigen, be antibody, b core igm)1 recall0 reports
- ARCHITECT 4P54-25Abbott Ireland Diagnostics · Test, hepatitis b (b core, be antigen, be antibody, b core igm)27 reports
- ADVIA Centaur® HBsII 10492138Siemens Healthcare Diagnostics Inc. · Test, Hepatitis B (B Core, Be Antigen, Be Antibody, B Core Igm)18 reports
- Atellica™ IM HBsII 10995604Siemens Healthcare Diagnostics Inc. · Test, hepatitis b (b core, be antigen, be antibody, b core igm)12 reports
Sources: FDA GUDID, MAUDE and Medical Device Recalls via openFDA. openFDA data is not validated for clinical or regulatory use.